Your browser doesn't support javascript.
loading
Rare Non-Neuroendocrine Pancreatic Tumours.
Mormul, Agata; Wloszek, Emilia; Nowoszewska, Julia; Fudalej, Marta; Budzik, Michal; Badowska-Kozakiewicz, Anna; Deptala, Andrzej.
Afiliação
  • Mormul A; Students' Scientific Organization of Cancer Cell Biology, Department of Oncology Propaedeutics, Medical University of Warsaw, 01-445 Warsaw, Poland.
  • Wloszek E; Students' Scientific Organization of Cancer Cell Biology, Department of Oncology Propaedeutics, Medical University of Warsaw, 01-445 Warsaw, Poland.
  • Nowoszewska J; Students' Scientific Organization of Cancer Cell Biology, Department of Oncology Propaedeutics, Medical University of Warsaw, 01-445 Warsaw, Poland.
  • Fudalej M; Department of Oncology Propaedeutics, Medical University of Warsaw, 01-445 Warsaw, Poland.
  • Budzik M; Department of Oncology Propaedeutics, Medical University of Warsaw, 01-445 Warsaw, Poland.
  • Badowska-Kozakiewicz A; Department of Oncology Propaedeutics, Medical University of Warsaw, 01-445 Warsaw, Poland.
  • Deptala A; Department of Oncology Propaedeutics, Medical University of Warsaw, 01-445 Warsaw, Poland.
Cancers (Basel) ; 15(8)2023 Apr 09.
Article em En | MEDLINE | ID: mdl-37190144
ABSTRACT
The most common tumour of the pancreas is ductal adenocarcinoma (PDAC). It remains one of the most lethal non-neuroendocrine solid tumours despite the use of a multi-approach strategy. Other, less-common neoplasms, which are responsible for 15% of pancreatic lesions, differ in treatment and prognosis. Due to the low incidence rate, there is a lack of information about the rarest pancreatic tumours. In this review, we described six rare pancreatic tumours intraductal papillary mucinous neoplasm (IPMN), mucinous cystadenoma (MCN), serous cystic neoplasm (SCN), acinar cell carcinoma (ACC), solid pseudopapillary neoplasm (SPN) and pancreatoblastoma (PB). We distinguished their epidemiology, clinical and gross features, covered the newest reports about courses of treatment and systematised differential diagnoses. Although the most common pancreatic tumour, PDAC, has the highest malignant potential, it is still essential to properly classify and differentiate less-common lesions. It is vital to continue the search for new biomarkers, genetic mutations and the development of more specific biochemical tests for determining malignancy in rare pancreatic neoplasms.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article